

PRESS RELEASE Stockholm 9 March 2022

ADDvise receives allocation decision worth approximately SEK 44 million

ADDvise Group AB (publ)'s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm-Gotland worth approximately SEK 44 million. The allocation decision consists of delivery of blood specimen collection equipment during a four-year period starting May 2022.

The allocation decision is subject to an appeal time expiring 18 March 2022.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisigroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 9 March 2022 at 11:10 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisigroup.com.